Drug might protect hearts of childhood leukemia survivors

June 4, 2012

About 75 percent of children with leukemia who take chemotherapy face life-threatening heart problems as they age, but an international study led by a University of Rochester Medical Center investigator shows that giving a cardio-protective drug during cancer treatment may prevent the damage.

Researchers and physicians will debate how to make young and their families aware of the risks of heart damage, and the best ways to manage the risks, in a special session today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Led by Barbara L. Asselin, M.D., professor of Pediatrics and Oncology at URMC, the study was sponsored by the Children's and the . It is believed to be one of the largest trials to evaluate the effectiveness of the drug Zinecard (dexrazoxane), at protecting the heart during treatment of . Asselin presented data and will also take part in a larger ASCO forum, during which hundreds of experts will discuss and second malignancies – the unfortunate, severe risks associated with aggressive treatment of children.

"Today the majority of children with leukemia will be cured," Asselin said. "As our young people survive, though, we believe we will see many more cardiac issues. It is a problem that must be fixed because it is the leading cause of death later in life among these patients."

One part of the equation involves getting teenagers and young adult cancer survivors, who tend to engage in riskier behaviors, to be aware of potential problems and make healthy lifestyle choices (no smoking; exercise; careful follow-up appointments with a physician), Asselin said.

Drugs such as Zinecard are also important, although the data so far has been inconsistent. The URMC study evaluated 537 patients for more than 10 years after they were treated for leukemia between 1996 and 2001. All received multi-agent chemotherapy that included doxorubicin, known to be toxic to the heart.

Patients were randomized to two groups, with or without a dose of intravenous Zinecard immediately prior to receiving the chemotherapy. Later, researchers assessed each patient for at three different points after chemotherapy. Using standard measures, they looked at heart muscle function and structure. (A common problem following doxorubicin therapy is heart enlargement and thinning of the ventricular walls.)

For both groups of patients, the five-year survival with no evidence of leukemia was the same. That data was encouraging and very important, Asselin said, because of concern in the pediatric community that adding Zinecard to the treatment regimen might interfere with the chemotherapy's ability to attack the .

In addition, the group that did not receive Zinecard had more episodes of acute , and researchers saw more damage over time to the heart structure and function, as compared to the group that did receive the cardio protective drug.

Earlier clinical trials of Zinecard in women with breast cancer, who had already received high doses of doxorubicin and needed more chemotherapy, showed that the drug could protect the heart during retreatment, Asselin said.

A problem with Zinecard, however, is that the URMC study also showed an increased rate of second malignancies in the children who received the heart drug. Although the higher rate did not reach conventional levels of statistical significance by research standards, it is worth noting and studying further, Asselin said.

One of the goals of the ASCO forum, in fact, will be to review all data on the use of the Zinecard and to debate the risks and benefits.

"We now have some very effective cancer treatments at our disposal," Asselin said. "But we really need to focus on promoting the good health of our survivors. Our care does not end with chemotherapy. Being there for many years into the future, and to help childhood survivors understand their risks, is so important."

Explore further: Childhood cancer drugs cure now, may cause problems later, research shows

Related Stories

Childhood cancer drugs cure now, may cause problems later, research shows

December 16, 2011
Will a drug used to treat childhood acute lymphoblastic leukemia and other pediatric cancers cause heart problems later in life?

Study reveals need for personalized approach in treatment of AML

May 16, 2011
A new discovery in mice by researchers at Wake Forest Baptist Medical Center may one day allow doctors to spare some patients with acute myeloid leukemia (AML) from toxic treatments, while also opening the door for new therapeutic ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.